{"id":"novartis-seasonal-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Injection site pain"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Upon administration, the vaccine introduces inactivated or attenuated influenza viruses or their components, which trigger an immune response. This leads to the production of antibodies that can recognize and neutralize the virus if encountered in the future.","oneSentence":"The vaccine stimulates the immune system to produce antibodies against specific influenza virus strains, thereby preventing infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:22.884Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza in individuals aged 6 months and older"}]},"trialDetails":[{"nctId":"NCT02091908","phase":"PHASE3","title":"Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-04","conditions":"Influenza, Human","enrollment":540},{"nctId":"NCT02107807","phase":"PHASE3","title":"Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-04","conditions":"Influenza, Human, Flu, Human, Flu, Avian","enrollment":539},{"nctId":"NCT00620815","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-11","conditions":"Influenza","enrollment":601},{"nctId":"NCT01368796","phase":"PHASE4","title":"Comparison of 4 Influenza Vaccines in Seniors","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-07","conditions":"Influenza Vaccine","enrollment":953},{"nctId":"NCT01209780","phase":"PHASE3","title":"Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"Seasonal Influenza","enrollment":3116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Novartis Seasonal Influenza Vaccine","genericName":"Novartis Seasonal Influenza Vaccine","companyName":"Seqirus","companyId":"seqirus","modality":"Biologic","firstApprovalDate":"","aiSummary":"The vaccine stimulates the immune system to produce antibodies against specific influenza virus strains, thereby preventing infection. Used for Prevention of seasonal influenza in individuals aged 6 months and older.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}